Dual structure-switching aptamer-mediated signal amplification cascade for SARS-CoV-2 detection

• Published in: Biosensors & bioelectronics 2024-09, Vol.259, p.116375, Article 116375
• Main Authors: Lim, Jaewoo, Son, Seong Uk, Ki, Jisun, Kim, Sunjoo, Lee, Jina, Jang, Soojin, Seo, Seung Beom, Jang, Hyowon, Kang, Taejoon, Jung, Juyeon, Kim, Eunjung, Lim, Eun-Kyung
• Format: Article
• Language: English
• Subjects: Coronavirus disease 2019; In vitro detection; Point-of-care test; Signal amplification; Structure-switching aptamer
• ISSN: 0956-5663; 1873-4235; 1873-4235
• DOI: 10.1016/j.bios.2024.116375

Since the outbreak of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at the end of 2019, the spread of the virus has posed a significant threat to public health and the global economy. This work proposed a one-step, dual-structure-switching aptamer-mediated signal amplification cascade for rapid and sensitive detection of the SARS-CoV-2 nucleocapsid protein. This system consisted of two DNA aptamers with structure-switching functionality and fuel DNA, where a cascade of strand hybridization and displacement triggered fluorescence generation and signal amplification. This aptamer-based amplification cascade required neither an amplification stage using enzymes nor pre-processing steps such as washing, viral isolation, and gene extraction. The assay could distinguish SARS-CoV-2 from other respiratory viruses and detect up to 1.0 PFU/assay of SARS-CoV-2 within 30 min at room temperature. In 35 nasopharyngeal clinical samples, the assay accurately assessed 25 positive and 10 negative clinical swab samples, which were confirmed using quantitative polymerase chain reaction. The strategy reported herein can help detect newly emerging pathogens and biomarkers of various diseases in liquid samples. In addition, the developed detection system consisting of only DNA and fluorophores can be widely integrated into liquid biopsy platforms for disease diagnosis.